Ultragenyx Pharmaceutical Inc.
RARE
$26.91
+8.29%
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for serious rare and ultra-rare genetic diseases. It is a specialized player in the niche orphan drug market, leveraging its expertise to address debilitating conditions with high unmet medical needs.…
RARE
Ultragenyx Pharmaceutical Inc.
$26.91
Investment Opinion: Should I buy RARE Today?
Based on a synthesis of the data, the objective assessment is a Hold for risk-averse investors and a Speculative Buy only for those with a high risk tolerance and a long-term horizon. The company's compelling revenue growth and niche focus are overshadowed by profound profitability issues and weak financial health. The current price, near 52-week lows, may discount significant bad news, but a sustainable turnaround requires a clear path to positive cash flow, which is not yet evident. Investors should await clearer signs of operational improvement or a more attractive valuation entry point.
Sign up to view all
RARE 12-Month Price Forecast
The investment case is balanced precariously between promising top-line growth in a rare disease niche and alarming bottom-line losses. The neutral stance reflects this dichotomy, with medium confidence due to the high uncertainty surrounding the company's path to sustainability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ultragenyx Pharmaceutical Inc.'s 12-month outlook, with a consensus price target around $34.98 and implied upside of +30.0% versus the current price.
Average Target
$34.98
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$22 - $35
Analyst target range
Wall Street analyst consensus data, including a target price and ratings distribution, is not provided in the inputs. The available data shows six analysts providing estimates, with average expected EPS of $5.58 and average expected revenue of $2.22 billion, but no explicit price targets or consensus rating is listed. Therefore, no sufficient analyst coverage summary is available for a definitive consensus statement.
Bulls vs Bears: RARE Investment Factors
Ultragenyx presents a classic high-risk, high-reward biotech profile. The company is growing revenue in a defensible niche but is burning significant cash with no clear path to profitability. The stock's severe technical decline reflects these fundamental challenges, creating a potential value trap or a deep-value opportunity depending on future execution.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 25.55% YoY to $207M.
- Niche Market Focus: Specializes in rare diseases with high unmet need and pricing power.
- Healthy Short-Term Liquidity: Current ratio of 2.48 indicates good ability to cover obligations.
- High Analyst Growth Expectations: Analysts forecast average EPS of $5.58 and revenue of $2.22B.
Bearish
- Persistent and Deep Losses: Net margin of -85.44% and negative free cash flow of -$472M TTM.
- Weak Financial Health: Negative debt-to-equity (-15.95) and negative equity position.
- Sustained Price Downtrend: Stock down 35.6% over 6 months, severely underperforming the SPY.
- High Short Interest: Short ratio of 4.37 indicates significant bearish sentiment.
RARE Technical Analysis
The stock has experienced a significant and sustained downtrend over the observed period, with the price declining from around $30 in October 2025 to approximately $19.30 by March 2026. Short-term performance has been weak, with the stock down 17.49% over the past month and 15.28% over the past three months, underperforming the broader market (SPY) significantly in both periods. The current price of $19.30 is near the bottom of its 52-week range of $18.41 to $42.37, representing a decline of over 48% from the yearly high and indicating the stock is in a deeply oversold position.
Beta
0.38
0.38x market volatility
Max Drawdown
-55.4%
Largest decline past year
52-Week Range
$18-$42
Price range past year
Annual Return
-26.6%
Cumulative gain past year
| Period | RARE Return | S&P 500 |
|---|---|---|
| 1m | +11.2% | +0.3% |
| 3m | +31.8% | +12.3% |
| 6m | -19.7% | +8.9% |
| 1y | -26.6% | +24.0% |
| ytd | +14.0% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RARE Fundamental Analysis
Revenue showed positive year-over-year growth of 25.55% in Q4 2025, reaching $207 million. However, the company remains deeply unprofitable, with a net loss of $129 million in the same quarter and a trailing net margin of -85.44%. Financial health is mixed; the company has a strong current ratio of 2.48, indicating good short-term liquidity, but carries a negative debt-to-equity ratio of -15.95 and has generated negative free cash flow of -$472 million over the trailing twelve months. Operational efficiency is challenged, with a negative Return on Assets (-22.04%) reflecting significant losses relative to its asset base, though a positive Return on Equity (7.19%) is noted, which may be distorted by the negative equity position.
Quarterly Revenue
$207000000.0B
2025-12
Revenue YoY Growth
+0.25%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$-472000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RARE Overvalued?
Given the company's consistent net losses (negative EPS of -$0.25 and net margin of -85.44%), traditional P/E analysis is not meaningful. Therefore, the valuation is assessed using the Price-to-Sales (PS) ratio of 3.37 and the Enterprise Value-to-Sales (EV/Sales) ratio of 3.63. These sales-based multiples reflect investor valuation of the company's revenue stream in the absence of profits. Data for a direct peer comparison within the biotechnology industry is not available in the provided inputs.
PE
-3.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -21x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.6x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is financial sustainability. The company's negative free cash flow of -$472 million over the trailing twelve months and deeply negative net margins raise serious concerns about its ability to continue funding operations without further dilutive capital raises. The negative debt-to-equity ratio indicates an impaired balance sheet, which could limit financial flexibility. Operational risks are high, as evidenced by a Return on Assets of -22.04%, showing inefficient use of capital. Market and sentiment risks are also pronounced, with the stock exhibiting high short interest (short ratio 4.37) and severe underperformance relative to the market, down over 60% on a 1-year relative strength basis. The lack of a near-term profitability catalyst, combined with a high forward P/E multiple, leaves the stock vulnerable to further downside if growth expectations are not met.
FAQ
The key risks are financial: the company is burning cash at a rate of -$472 million TTM and has a negative debt-to-equity ratio (-15.95), indicating a weak balance sheet. There is also significant execution risk in achieving analyst profit forecasts (EPS of $5.58). Market sentiment risk is high, with a short ratio of 4.37 and the stock down 48% from its 52-week high, reflecting deep pessimism.
A 12-month forecast presents a wide range of outcomes. The base case (50% probability) sees the stock trading between $20 and $30, driven by steady revenue growth but ongoing losses. A bull case (25%) could see a rally to the $30-$42 range on profit improvement, while a bear case (25%) could see a retest of the 52-week low near $18. The average analyst revenue forecast for the coming year is $2.22 billion.
RARE's valuation is difficult to assess due to its losses. Based on sales multiples, it trades at a Price-to-Sales ratio of 3.37 and an EV/Sales of 3.63. Given the persistent and heavy losses (negative EPS of -$0.25), these multiples could be considered high, suggesting the stock is not clearly undervalued. The high forward P/E of 238.5 reflects extreme growth expectations that may not materialize.
RARE is not a good stock to buy for most investors seeking stability or profitability. It is a highly speculative buy only for investors with a high risk tolerance who believe in its long-term rare disease pipeline. The company is growing revenue (25.55% YoY in Q4) but is deeply unprofitable with a net margin of -85.44% and negative free cash flow, making it a very risky proposition.
RARE is unsuitable for short-term investment due to its high volatility, negative cash flow, and bearish sentiment (high short interest). It may only be considered for a long-term investment horizon (5+ years) by investors who believe the company can eventually achieve profitability in its niche rare disease markets. The long timeline for biotech pipeline development and commercialization aligns with a long-term hold strategy, if at all.